XML 67 R49.htm IDEA: XBRL DOCUMENT v3.25.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of stock options activity
Number of
options
outstanding		Weighted-
average
exercise
price
(Per share)		Weighted-
average
remaining
contractual
term
(In years)		Aggregate
intrinsic
value
(In thousands)
Outstanding options as of December 31, 20241,322,176 $74.15 3.05$74,838 
Exercised(420,056)$14.87 
Outstanding options as of December 31, 2025902,120 $101.75 2.87$59,701 
Options vested and exercisable as of December 31, 2025902,120 $101.75 2.87$59,701 
Schedule of weighted average grant date fair value
Year Ended December 31,
202520242023
(In thousands, except per share amounts)
Aggregate intrinsic value of stock options exercised (1)
$41,976 $8,649 $15,242 
Total estimated grant date fair value of options vested$844 $9,351 $28,619 
____________________________________
(1) Aggregate intrinsic value represents the difference between the fair value of the Company’s Class A common stock as reported on the New York Stock Exchange and the exercise price of outstanding “in-the-money” options.
Schedule of restricted stock unit
Number of
awards
outstanding		Weighted-
average
grant date
fair value
(Per share)		Aggregate
intrinsic
value
(In thousands)
Unvested RSUs as of December 31, 202418,386,271 $71.96 $1,394,966 
Granted4,728,094 $119.02 
Vested(6,944,005)$84.28 
Forfeited and canceled(2,506,383)$78.06 
Unvested RSUs as of December 31, 202513,663,977 $80.86 $1,943,564 
Schedule of employee stock purchase plan
The Company used the following assumptions in the Black-Scholes option pricing model to estimate the fair value of the purchase rights issued under the 2016 ESPP:
Year Ended December 31,
Employee Stock Purchase Plan:202520242023
Fair value of common stock
$116.34 - $120.22
$61.54 - $96.41
$47.36 - $61.55
Expected term (in years)0.50
0.50
0.50
Expected volatility
57.8% - 58.7%
38.6% - 41.8%
45.8% - 57.1%
Risk-free interest rate
3.8% - 4.3%
4.4% - 5.4%
5.3% - 5.4%
Schedule of stock based compensation expense
The Company recorded stock-based compensation expense as follows:
Year Ended December 31,
202520242023
(In thousands)
Cost of revenue$16,570 $22,001 $26,343 
Research and development326,767 330,933 331,526 
Sales and marketing136,998 135,331 183,389 
General and administrative118,319 125,164 121,584 
Restructuring costs1,753 3,178 13,015 
Total$600,407 $616,607 $675,857